Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimer…
Biotechnology
US, South San Francisco [HQ]
Revenue Breakdowns
Segment Analysis Beta
The financial segments are sourced from the SEC' 10-K statement.Revenue By Top Segments
Allogene Therapeutics, Inc. can't present it's sankey chart.
Historical Revenue By Segment
Last 3Y, in million USDAllogene Therapeutics, Inc. can't present revenue by segment
Get PRO Today
With PRO you can bypass the blur for the segment revenues of Allogene Therapeutics, Inc..
If you want to see a demo, head over to the financial segments of AAPL